drugset / Trial / NCT04061109
Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
NaSingle-groupOpen-labelPrevention
Summary
This is a multi-center, open-label, single-arm trial to evaluate the efficacy and safety of Recombinant Coagulation Factor VIII in patients with hemophilia A . Recombinant Coagulation Factor VIII is prophylactic administrated 25 - 35 IU/kg once every other day or three times per week which should be continuous for 24 weeks.
Timeline
- Start
- 2019-05-15
- Primary completion
- 2020-03
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCT800 | Protein / enzyme biologic | 25 iu/kg | Other |
| Subject | SCT800 | Protein / enzyme biologic | 35 iu/kg | Other |